Hematology

What is hematology?

Hematology is the study of disorders that affect the blood and related structures, such as red blood cells, white blood cells, platelets, lymph, bone marrow and spleen.

Hematology conditions and cancer treatment

Treatment for all blood disorders at Henry Ford Health is coordinated through an integrated team of hematologists and oncologists, who also treat cancer.

Blood disorders we treat

Benign (non-cancerous) hematology conditions:

• Anemia
• Disorders of white blood cells and platelets
• Bleeding disorders, including but not limited to: hemophilia, von Willebrand disease, Glanzmann’s Thrombasthenia, Bernard Soulier disease, and platelet dysfunction
• Blood clotting disorders, including but not limited to: deep vein thrombosis (DVT), pulmonary embolism (PE), antiphospholipid syndrome, inherited and other acquired clotting disorders
• Sickle cell disease
• Thalassemia
• Paroxysmal nocturnal hemoglobinuria

Malignant (cancerous) hematology conditions:

• Myeloproliferative disorders
• Myelodysplastic syndrome (MDS)
• Leukemia
• Lymphoma
• Myeloma, including protein disorders such as: amyloidosis, light chain deposition disease, cryoglobulinemia and monoclonal gammopathy of undetermined significance (MGUS)

Why choose Henry Ford for your hematology care?

• Expertise: Our hematologists have experience treating all types of blood disorders, including rare and complex cases.
• Integrated team: Our hematologists and oncologists collaborate to provide the most advanced care available as well as support throughout your treatment journey.
• Specialized care: We are experienced in genetic research and testing. We also offer the only comprehensive programs in Michigan for hemophilia and sickle cell disease treatment. 
• Advanced treatment: As a teaching hospital offering subspecialty training in blood disorders, Henry Ford stays on the forefront of our rapidly evolving field. Our hematology faculty, residents and fellows work together to bring you the latest therapies, including innovative treatments such as stem cell transplantation and CAR T-cell therapy, newer immunotherapies, and gene therapy.
• Clinical trials and research: You may be eligible for new treatment options, including emerging therapies that aren’t widely available. We are involved with multiple research studies evaluating the cause of various blood disorders and their management. These are done in collaboration with other institutions as well as National Cancer Institute-designated cooperative groups and other research consortiums. These benefit patients with both non-cancerous and cancerous blood disorders.